{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:44:00Z","timestamp":1777776240658,"version":"3.51.4"},"reference-count":18,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Introduction.<\/jats:bold>\n                    Commonly prescribed medications are associated with various gastrointestinal (GI) side effects but few data are available on prescription medication use and polypharmacy in a gastroenterology outpatient practice. We aimed to examine the prevalence of polypharmacy, defined as the simultaneous use of 5 or more medications.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods.<\/jats:bold>\n                    A descriptive correlational study of consecutive outpatient consultations in 988 patients referred to a tertiary gastroenterology practice. Main outcome measurements were frequency of prescription medication use and polypharmacy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.<\/jats:bold>\n                    The most common GI symptoms were abdominal pain (72%), nausea (57%), and constipation (53%). The frequency of polypharmacy was 10%. Eighty percent of patients took at least one medication and 60% took two or more. The most frequently used medication classes were proton pump inhibitors (43%), followed by benzodiazepines (30%), selective serotonin-reuptake or norepinephrine-reuptake inhibitors (28%), non-steroidal anti-inflammatory drugs (27%), and opioids (21%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion.<\/jats:bold>\n                    There was a higher use of prescription medicine including antidepressants, and a lower frequency of polypharmacy in our study cohort compared to the general population. The use of medications may have contributed to the symptoms leading to our study\u2019s population GI consultation.\n                  <\/jats:p>","DOI":"10.2478\/rjim-2020-0016","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T05:56:59Z","timestamp":1594360619000},"page":"228-232","source":"Crossref","is-referenced-by-count":2,"title":["Medication use and polypharmacy in patients referred to a tertiary gastroenterology practice"],"prefix":"10.2478","volume":"58","author":[{"given":"Abimbola","family":"Chris-Olaiya","sequence":"first","affiliation":[{"name":"Department of Hepatology , University of Kentucky , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Palmer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Mayo Clinic Florida , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Stancampiano","sequence":"additional","affiliation":[{"name":"Department of Medicine , Mayo Clinic Florida , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Lacy","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Mayo Clinic Florida , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Heckman","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics , Mayo Clinic Florida , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razvan","family":"Chirila","sequence":"additional","affiliation":[{"name":"Department of Medicine , Mayo Clinic Florida , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveed","family":"Nikpour","sequence":"additional","affiliation":[{"name":"Mayo Clinic Florida, Clinical Research Internship Study Program , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Mcleod","sequence":"additional","affiliation":[{"name":"Mayo Clinic Florida, Clinical Research Internship Study Program , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Ryan","sequence":"additional","affiliation":[{"name":"Mayo Clinic Florida, Clinical Research Internship Study Program , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Maillis","sequence":"additional","affiliation":[{"name":"Mayo Clinic Florida, Clinical Research Internship Study Program , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Vargas","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics , Mayo Clinic Florida , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Bouras","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Mayo Clinic Florida , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"2026042914162482613_j_rjim-2020-0016_ref_001_w2aab3b7b2b1b6b1ab1ab1Aa","doi-asserted-by":"crossref","unstructured":"1. TINETTI ME, BOGARDUS ST, AGOSTINI JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004; 351(27):2870\u20132874.10.1056\/NEJMsb04245815625341","DOI":"10.1056\/NEJMsb042458"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_002_w2aab3b7b2b1b6b1ab1ab2Aa","doi-asserted-by":"crossref","unstructured":"2. GANDHI TK, WEINGART SN, BORUS J, SEGER AC, PETERSON J, BURDICK E, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003; 348(16):1556\u20131564.10.1056\/NEJMsa02070312700376","DOI":"10.1056\/NEJMsa020703"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_003_w2aab3b7b2b1b6b1ab1ab3Aa","doi-asserted-by":"crossref","unstructured":"3. KANTOR ED, REHM CD, HAAS JS, CHAN AT, GIOVANUCCI EL. Trends in prescription drug use among adults in the United States from 1999\u20132012. Jama. 2015; 314(17):1818\u20131831.10.1001\/jama.2015.13766475216926529160","DOI":"10.1001\/jama.2015.13766"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_004_w2aab3b7b2b1b6b1ab1ab4Aa","doi-asserted-by":"crossref","unstructured":"4. EVERHART JE, RUHL CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009; 136(2):376\u2013386.10.1053\/j.gastro.2008.12.01519124023","DOI":"10.1053\/j.gastro.2008.12.015"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_005_w2aab3b7b2b1b6b1ab1ab5Aa","doi-asserted-by":"crossref","unstructured":"5. IMHANN F, BONDER MJ, VILA AV, FU J, MUJAGIC Z, VORK L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016; 65(5):740\u2013748.10.1136\/gutjnl-2015-310376485356926657899","DOI":"10.1136\/gutjnl-2015-310376"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_006_w2aab3b7b2b1b6b1ab1ab6Aa","doi-asserted-by":"crossref","unstructured":"6. SPIEGEL BM, CHEY WD, CHANG L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol. 2008; 103(12):2972\u20132976.10.1111\/j.1572-0241.2008.01992.x294908419086951","DOI":"10.1111\/j.1572-0241.2008.01992.x"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_007_w2aab3b7b2b1b6b1ab1ab7Aa","doi-asserted-by":"crossref","unstructured":"7. HOLZER P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs. 2007; 16(2):181\u2013194.10.1517\/13543784.16.2.18117243938","DOI":"10.1517\/13543784.16.2.181"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_008_w2aab3b7b2b1b6b1ab1ab8Aa","unstructured":"8. LACY BE. Effects of Opioids on Esophageal Dysfunction. Gastroenterol Hepatol (N Y). 2016; 12(5):323\u2013325."},{"key":"2026042914162482613_j_rjim-2020-0016_ref_009_w2aab3b7b2b1b6b1ab1ab9Aa","doi-asserted-by":"crossref","unstructured":"9. CAMILLERI M, LEMBO A, KATZKA DA. Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits. Clin Gastroenterol Hepatol. 2017; 15(9):1338\u20131349.10.1016\/j.cgh.2017.05.014556567828529168","DOI":"10.1016\/j.cgh.2017.05.014"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_010_w2aab3b7b2b1b6b1ab1ac10Aa","doi-asserted-by":"crossref","unstructured":"10. CHIAL HJ, CAMILLERI M, BURTON D, THOMFORDE G, OLDEN KW, STEPHENS D. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol. 2003; 284(1):G130\u2013137.10.1152\/ajpgi.00266.200212488239","DOI":"10.1152\/ajpgi.00266.2002"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_011_w2aab3b7b2b1b6b1ab1ac11Aa","doi-asserted-by":"crossref","unstructured":"11. HALPERT A, DALTON CB, DIAMANT NE, TONER BB, HU Y, MORRIS CB, et al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol. 2005; 100(3):664\u2013671.10.1111\/j.1572-0241.2005.30375.x15743366","DOI":"10.1111\/j.1572-0241.2005.30375.x"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_012_w2aab3b7b2b1b6b1ab1ac12Aa","doi-asserted-by":"crossref","unstructured":"12. ZHONG W, MARADIT-KREMERS H, ST AUVER JL, YAWN BP, EBBERT JO, ROGER VL, et al. Age and sex patterns of drug prescribing in a defined American population. Mayo Clin Proc. 2013; 88(7):697\u2013707.10.1016\/j.mayocp.2013.04.021375482623790544","DOI":"10.1016\/j.mayocp.2013.04.021"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_013_w2aab3b7b2b1b6b1ab1ac13Aa","doi-asserted-by":"crossref","unstructured":"13. FRANSSEN FM, SPRUIT MA, WOUTERS EF. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011; 6:493\u2013501.10.2147\/COPD.S24443320676522069360","DOI":"10.2147\/COPD.S24443"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_014_w2aab3b7b2b1b6b1ab1ac14Aa","doi-asserted-by":"crossref","unstructured":"14. HOFFMAN F, VAN DES BUSSCHE H, WIESE B, SCHON G, KOLLER D, EISELE M, et al. Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia. BMC Psychiatry. 2011; 11:190.10.1186\/1471-244X-11-190326215422145796","DOI":"10.1186\/1471-244X-11-190"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_015_w2aab3b7b2b1b6b1ab1ac15Aa","doi-asserted-by":"crossref","unstructured":"15. PATEL PJ, HAYWARD KL, RUDRA R, HORSFALL LU, HOSSAIN F, WILLIAMS S, et al. Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management. Medicine (Baltimore). 2017; 96(26):e6761.10.1097\/MD.0000000000006761550001628658094","DOI":"10.1097\/MD.0000000000006761"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_016_w2aab3b7b2b1b6b1ab1ac16Aa","doi-asserted-by":"crossref","unstructured":"16. CALDERON-LARRANAGA A, GIMENO-FELIU LA, GONZALES-RUBIO F, POBLADOR-PLOU B, LAILA-SAN JOSE M, ABAD-DIEZ JM, et al. Polypharmacy patterns: unravelling systematic associations between prescribed medications. PLoS One. 2013; 8(12):e84967.10.1371\/journal.pone.0084967386992024376858","DOI":"10.1371\/journal.pone.0084967"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_017_w2aab3b7b2b1b6b1ab1ac17Aa","doi-asserted-by":"crossref","unstructured":"17. MASNOON A, SHAKIB S, KALISCH-ELLETT L, CAUGHEY GE. What is polypharmacy? A systematic review of definitions. BMC Geriatrics 2017; 17:230.10.1186\/s12877-017-0621-2563556929017448","DOI":"10.1186\/s12877-017-0621-2"},{"key":"2026042914162482613_j_rjim-2020-0016_ref_018_w2aab3b7b2b1b6b1ab1ac18Aa","doi-asserted-by":"crossref","unstructured":"18. BEUSCART JB, PETIT S, GAUTIER S, WIERRE P, BALCAEN T, LEFEBVRE JM, et al. Polypharmacy in older patients: identifying the need for support by a community pharmacist. BMC Geriatrics 2019; 19(1):277.10.1186\/s12877-019-1276-y680248131638909","DOI":"10.1186\/s12877-019-1276-y"}],"container-title":["Romanian Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/rjim\/58\/4\/article-p228.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/rjim-2020-0016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:21:20Z","timestamp":1777486880000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/rjim-2020-0016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12,17]]},"published-print":{"date-parts":[[2020,12,1]]}},"alternative-id":["10.2478\/rjim-2020-0016"],"URL":"https:\/\/doi.org\/10.2478\/rjim-2020-0016","relation":{},"ISSN":["2501-062X"],"issn-type":[{"value":"2501-062X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}